New approach aims to make treatment more accessible for children with rare brain disorders
McGill University researchers have developed and tested a new way to facilitate the creation of personalized genetic therapies for children with rare neurodevelopmental disorders. Currently, many children suffering from rare disorders are left without a realistic path to treatment, given that the underlying genetic changes may affect only a handful of patients. As such, there is a need for…
Researchers at McGill University have devised a novel method to make personalized genetic therapies more accessible for children with rare brain disorders. Traditionally, many children with these conditions face limited treatment options due to the rarity of their genetic changes. The study, published in the American Journal of Human Genetics, introduces a framework that treats diagnosis as the starting point for therapeutic evaluation rather than the end of a diagnostic journey.
The researchers propose a workflow that connects genetic diagnosis to the screening and testing of individualized therapies, bridging the gap between a patient's diagnosis and the development of a tailored treatment.
Lead author Julia Macintosh, a Ph.D. student in McGill's Department of Neurology and Neurosurgery, explained that the new approach creates a single, integrated process for patients, moving from genetic diagnosis through treatment development and testing. This method streamlines the development of personalized therapies, which is crucial for children with rare neurodevelopmental disorders who currently lack realistic treatment pathways.
Assistant Professor Carl Ernst, the senior author and head of the Interventional Genetics Unit at the Neuro, noted that this model has been developed in collaboration with CHU Sainte-Justine, aiming to support families in Quebec and potentially benefit genetic diagnostic centers worldwide.
The research team utilized a patient's blood sample to generate brain cells carrying the same genetic mutation as the individual. These cells were then used to study the disorder and evaluate potential treatments in the laboratory. As a proof of concept, they developed and tested an experimental RNA therapy for a child with Kleefstra syndrome, a rare genetic disorder characterized by developmental delays, intellectual disability, and communication difficulties.
The RNA therapy was evaluated in the laboratory cells, with further research required before human trials can begin.
The study emphasizes that while many technologies necessary for personalized genetic therapies already exist, the challenge now lies in integrating these technologies into healthcare systems to ensure broader patient access. The paper, titled "Integrating clinical diagnostics with interventional genetics for neurodevelopmental disorders," highlights the collaborative effort at McGill University and CHU Sainte-Justine, with the goal of improving the treatment options for children with rare brain disorders.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.